
Charles E. Cooley
Examiner (ID: 18400, Phone: (571)272-1139 , Office: P/1774 )
| Most Active Art Unit | 1774 |
| Art Unit(s) | 1797, 1774, 1723, 2402, 1754, 3405 |
| Total Applications | 4063 |
| Issued Applications | 3143 |
| Pending Applications | 300 |
| Abandoned Applications | 659 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 15147817
[patent_doc_number] => 20190352386
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-11-21
[patent_title] => HIGHLY POTENT MONOCLONAL ANTIBODIES TO ANGIOGENIC FACTORS
[patent_app_type] => utility
[patent_app_number] => 15/759471
[patent_app_country] => US
[patent_app_date] => 2016-09-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14120
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 19
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15759471
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/759471 | HIGHLY POTENT MONOCLONAL ANTIBODIES TO ANGIOGENIC FACTORS | Sep 12, 2016 | Abandoned |
Array
(
[id] => 15978029
[patent_doc_number] => 10669323
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-06-02
[patent_title] => Methods of treating metabolic disorders with dual function fibroblast growth factor 21 proteins
[patent_app_type] => utility
[patent_app_number] => 15/248712
[patent_app_country] => US
[patent_app_date] => 2016-08-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 17
[patent_figures_cnt] => 29
[patent_no_of_words] => 34230
[patent_no_of_claims] => 15
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 85
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15248712
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/248712 | Methods of treating metabolic disorders with dual function fibroblast growth factor 21 proteins | Aug 25, 2016 | Issued |
Array
(
[id] => 11434877
[patent_doc_number] => 20170035897
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-02-09
[patent_title] => 'Modified Relaxin Polypeptides and Their Uses'
[patent_app_type] => utility
[patent_app_number] => 15/239277
[patent_app_country] => US
[patent_app_date] => 2016-08-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 26
[patent_figures_cnt] => 26
[patent_no_of_words] => 103768
[patent_no_of_claims] => 22
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15239277
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/239277 | Method of treating heart failure with modified relaxin polypeptides | Aug 16, 2016 | Issued |
Array
(
[id] => 13368983
[patent_doc_number] => 20180236032
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-08-23
[patent_title] => COMBINATION COMPOSITION COMPRISING FGF-18 COMPOUND
[patent_app_type] => utility
[patent_app_number] => 15/751885
[patent_app_country] => US
[patent_app_date] => 2016-08-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8982
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15751885
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/751885 | COMBINATION COMPOSITION COMPRISING FGF-18 COMPOUND | Aug 10, 2016 | Abandoned |
Array
(
[id] => 15086471
[patent_doc_number] => 20190338046
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-11-07
[patent_title] => BINDING PROTEINS AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 15/748111
[patent_app_country] => US
[patent_app_date] => 2016-07-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 68695
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15748111
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/748111 | Beta klotho-binding proteins | Jul 28, 2016 | Issued |
Array
(
[id] => 11421335
[patent_doc_number] => 20170029479
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-02-02
[patent_title] => 'Modified FGF-21 Polypeptides Comprising an Internal Deletion and Uses Thereof'
[patent_app_type] => utility
[patent_app_number] => 15/215329
[patent_app_country] => US
[patent_app_date] => 2016-07-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 81
[patent_figures_cnt] => 81
[patent_no_of_words] => 89326
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15215329
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/215329 | Modified FGF-21 polypeptides comprising an internal deletion and uses thereof | Jul 19, 2016 | Issued |
Array
(
[id] => 12166156
[patent_doc_number] => 09884919
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2018-02-06
[patent_title] => 'Methods of treatment with bispecific antibodies binding to beta-klotho and fibroblast growth factor receptor 1'
[patent_app_type] => utility
[patent_app_number] => 15/214160
[patent_app_country] => US
[patent_app_date] => 2016-07-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 43
[patent_figures_cnt] => 80
[patent_no_of_words] => 42507
[patent_no_of_claims] => 16
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 186
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15214160
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/214160 | Methods of treatment with bispecific antibodies binding to beta-klotho and fibroblast growth factor receptor 1 | Jul 18, 2016 | Issued |
Array
(
[id] => 11381654
[patent_doc_number] => 20170007711
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-01-12
[patent_title] => 'PEGYLATED GROWTH HORMONE ANTAGONISTS'
[patent_app_type] => utility
[patent_app_number] => 15/204425
[patent_app_country] => US
[patent_app_date] => 2016-07-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7005
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15204425
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/204425 | PEGYLATED GROWTH HORMONE ANTAGONISTS | Jul 6, 2016 | Abandoned |
Array
(
[id] => 11113638
[patent_doc_number] => 20160310610
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2016-10-27
[patent_title] => 'Cancer Treatments'
[patent_app_type] => utility
[patent_app_number] => 15/202115
[patent_app_country] => US
[patent_app_date] => 2016-07-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 57
[patent_figures_cnt] => 57
[patent_no_of_words] => 20267
[patent_no_of_claims] => 5
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15202115
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/202115 | Nanoparticle complexes of anti-CD20 antibodies, albumin and paclitaxel | Jul 4, 2016 | Issued |
Array
(
[id] => 16105637
[patent_doc_number] => 10695403
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-06-30
[patent_title] => Use of FGF19 to increase muscle fiber size
[patent_app_type] => utility
[patent_app_number] => 15/739238
[patent_app_country] => US
[patent_app_date] => 2016-06-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 7
[patent_figures_cnt] => 7
[patent_no_of_words] => 9107
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 36
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15739238
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/739238 | Use of FGF19 to increase muscle fiber size | Jun 23, 2016 | Issued |
Array
(
[id] => 14273815
[patent_doc_number] => 20190134192
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-05-09
[patent_title] => TM4SF19 AS MARKER FOR DIAGNOSING OBESITY AND METHOD USING SAME
[patent_app_type] => utility
[patent_app_number] => 15/739228
[patent_app_country] => US
[patent_app_date] => 2016-06-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5742
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 45
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15739228
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/739228 | TM4SF19 AS MARKER FOR DIAGNOSING OBESITY AND METHOD USING SAME | Jun 23, 2016 | Abandoned |
Array
(
[id] => 11127989
[patent_doc_number] => 20160324964
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2016-11-10
[patent_title] => 'CANCER TREATMENTS'
[patent_app_type] => utility
[patent_app_number] => 15/187672
[patent_app_country] => US
[patent_app_date] => 2016-06-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 56
[patent_figures_cnt] => 56
[patent_no_of_words] => 20301
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15187672
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/187672 | Nanoparticle complexes of albumin, paclitaxel, and panitumumab for treatment of cancer | Jun 19, 2016 | Issued |
Array
(
[id] => 11085384
[patent_doc_number] => 20160282350
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2016-09-29
[patent_title] => 'METHODS OF DIAGNOSING CANCER'
[patent_app_type] => utility
[patent_app_number] => 15/178595
[patent_app_country] => US
[patent_app_date] => 2016-06-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 6
[patent_no_of_words] => 21650
[patent_no_of_claims] => 16
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15178595
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/178595 | METHODS OF DIAGNOSING CANCER | Jun 9, 2016 | Abandoned |
Array
(
[id] => 16041081
[patent_doc_number] => 10682391
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-06-16
[patent_title] => Inhibitors of IGFBP3 binding to TMEM219 for treatment of intestinal diseases
[patent_app_type] => utility
[patent_app_number] => 15/579573
[patent_app_country] => US
[patent_app_date] => 2016-06-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 44
[patent_figures_cnt] => 182
[patent_no_of_words] => 24407
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 58
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15579573
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/579573 | Inhibitors of IGFBP3 binding to TMEM219 for treatment of intestinal diseases | Jun 5, 2016 | Issued |
Array
(
[id] => 11060780
[patent_doc_number] => 20160257742
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2016-09-08
[patent_title] => 'THERAPEUTIC ANTIBODIES AND USES THEREOF'
[patent_app_type] => utility
[patent_app_number] => 15/163391
[patent_app_country] => US
[patent_app_date] => 2016-05-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 2
[patent_no_of_words] => 13370
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15163391
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/163391 | Antibody targeting stem cell factor | May 23, 2016 | Issued |
Array
(
[id] => 13297529
[patent_doc_number] => 20180200301
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-07-19
[patent_title] => Low-Oxygen-Treated Mesenchymal Stem Cell and Use Thereof
[patent_app_type] => utility
[patent_app_number] => 15/576091
[patent_app_country] => US
[patent_app_date] => 2016-05-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6966
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 22
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15576091
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/576091 | Low-Oxygen-Treated Mesenchymal Stem Cell and Use Thereof | May 19, 2016 | Abandoned |
Array
(
[id] => 11054443
[patent_doc_number] => 20160251405
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2016-09-01
[patent_title] => 'APPLICATION OF METRNL PROTEIN IN PREPARING HYPOLIPIDEMIC, HYPOGLYCEMIC MEDICINE'
[patent_app_type] => utility
[patent_app_number] => 15/137606
[patent_app_country] => US
[patent_app_date] => 2016-04-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 1
[patent_no_of_words] => 1921
[patent_no_of_claims] => 3
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15137606
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/137606 | APPLICATION OF METRNL PROTEIN IN PREPARING HYPOLIPIDEMIC, HYPOGLYCEMIC MEDICINE | Apr 24, 2016 | Abandoned |
Array
(
[id] => 13490209
[patent_doc_number] => 20180296647
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-10-18
[patent_title] => PROPHYLACTIC AND THERAPEUTIC AGENT FOR RETT SYNDROME (RTT) COMPRISING GHRELIN AS ACTIVE INGREDIENT
[patent_app_type] => utility
[patent_app_number] => 15/768101
[patent_app_country] => US
[patent_app_date] => 2016-04-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5799
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -2
[patent_words_short_claim] => 11
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15768101
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/768101 | PROPHYLACTIC AND THERAPEUTIC AGENT FOR RETT SYNDROME (RTT) COMPRISING GHRELIN AS ACTIVE INGREDIENT | Apr 19, 2016 | Abandoned |
Array
(
[id] => 11066279
[patent_doc_number] => 20160263243
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2016-09-15
[patent_title] => 'ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS'
[patent_app_type] => utility
[patent_app_number] => 15/069853
[patent_app_country] => US
[patent_app_date] => 2016-03-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 37
[patent_figures_cnt] => 37
[patent_no_of_words] => 40616
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15069853
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/069853 | Antibody drug conjugates (ADC) that bind to 191P4D12 proteins | Mar 13, 2016 | Issued |
Array
(
[id] => 11062004
[patent_doc_number] => 20160258966
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2016-09-08
[patent_title] => 'Compositions and Methods for Diagnosing and Treating Diseases and Disorders Associated With D-DT'
[patent_app_type] => utility
[patent_app_number] => 15/066404
[patent_app_country] => US
[patent_app_date] => 2016-03-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 15
[patent_figures_cnt] => 15
[patent_no_of_words] => 29500
[patent_no_of_claims] => 36
[patent_no_of_ind_claims] => 7
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15066404
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/066404 | Compositions and Methods for Diagnosing and Treating Diseases and Disorders Associated With D-DT | Mar 9, 2016 | Abandoned |